Sugi Predict

Sugi Predict / Targets / UBLCP1

UBLCP1

Ubiquitin-like domain-containing CTD phosphatase 1 · Q8WVY7 · UBLCP1 on Sugi Atlas →

156 patent compounds predicted against UBLCP1, 82 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5319688 SCHEMBL5319688 0.47 4/20
SCHEMBL5275716 SCHEMBL5275716 0.47 4/20
SCHEMBL5695165 SCHEMBL5695165 0.43 3/20
SCHEMBL27938060 SCHEMBL27938060 0.39 3/20
SCHEMBL1812530 SCHEMBL1812530 0.45 2/20
SCHEMBL5381758 SCHEMBL5381758 0.44 2/20
SCHEMBL13734856 SCHEMBL13734856 0.41 2/20
SCHEMBL14366091 SCHEMBL14366091 0.40 2/20
SCHEMBL4670205 SCHEMBL4670205 0.39 2/20
SCHEMBL16375396 SCHEMBL16375396 1.00 1/20
SCHEMBL30366901 SCHEMBL30366901 1.00 1/20
SCHEMBL16376118 SCHEMBL16376118 0.92 1/20
SCHEMBL17669849 SCHEMBL17669849 0.86 1/20
SCHEMBL16375397 SCHEMBL16375397 0.83 1/20
SCHEMBL16376121 SCHEMBL16376121 0.83 1/20
SCHEMBL18323176 SCHEMBL18323176 0.79 1/20
SCHEMBL16375402 SCHEMBL16375402 0.77 1/20
SCHEMBL30367054 SCHEMBL30367054 0.77 1/20
SCHEMBL16376122 SCHEMBL16376122 0.77 1/20
SCHEMBL18323109 SCHEMBL18323109 0.77 1/20

Clinical trials — most relevant to UBLCP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery EARLY_PHASE1COMPLETED
The Role of Fibroblast Activation in Uterine Fibroid nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
The Role of TBC1D4 in Exercise- and Insulin-induced Glucose Metabolism in Human Skeletal Muscle nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Phosphoproteomic Profile of Children With Down Syndrome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis nanCOMPLETED
Gene Expression in Inflammatory Bowel Disease nanENROLLING_BY_INVITATION
PCD New Gene Discovery nanCOMPLETED
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a UBLCP1 binder may also engage these)

ProteinNameSimilarity
Q2KJD7 — 1.000 Q2KJD7 →
Q5R4C4 — 1.000 Q5R4C4 →
Q8BGR9 — 1.000 Q8BGR9 →
Q5ZJJ8 — 1.000 Q5ZJJ8 →
Q5FWT7 — 1.000 Q5FWT7 →
Q6DI37 — 1.000 Q6DI37 →
Q641F1 — 1.000 Q641F1 →
Q28EX9 — 1.000 Q28EX9 →
Q8W3M6 — 0.990 Q8W3M6 →
Q6P4T2 — 0.972 Q6P4T2 →
SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 0.971 landscape →
Q5R882 — 0.968 Q5R882 →
Q5R6E0 — 0.966 Q5R6E0 →
Q5RBI3 — 0.966 Q5RBI3 →
Q5R8R4 — 0.966 Q5R8R4 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.965 landscape →
Q5IH13 — 0.965 Q5IH13 →
A4FUD3 — 0.965 A4FUD3 →
Q64514 — 0.965 Q64514 →
A0FKG7 — 0.965 A0FKG7 →
Q5F3X4 — 0.964 Q5F3X4 →
Q6TGY8 — 0.964 Q6TGY8 →
Q6H8D6 — 0.964 Q6H8D6 →
Q7ZVK4 — 0.964 Q7ZVK4 →
Q5E993 — 0.963 Q5E993 →
F1LNJ2 — 0.963 F1LNJ2 →
Q42450 — 0.963 Q42450 →
B0BNG0 — 0.963 B0BNG0 →
F1QR43 — 0.963 F1QR43 →
Q01217 — 0.963 Q01217 →